Business Wire

I-COM

30.9.2020 05:03:53 CEST | Business Wire | Press release

Share
Harm Reduction Policies Essential to Prevent Cancer, Say I-Com and MEPs

I-Com, the Institute for Competitiveness, yesterday hosted a landmark roundtable in the context of Europe’s Beating Cancer Plan, summarised here , bringing together policymakers from across the political spectrum, academics and scientists to present the findings of their study on best practices to beat cancer.

During the roundtable, the discussion analysed best practices and successes of harm reduction policies across Europe. Enabling citizens to live healthier lifestyles by making less risky products accessible, such as vaping devices for smokers, by conducting education and awareness campaigns about responsible alcohol consumption and by building infrastructure promoting physical activity are examples of the core ideas driving the evidence-based approach behind harm reduction policy. During the public consultations on the Beating Cancer Plan, 20% of submissions highlighted harm reduction’s potential role.

Dolors Montserrat, Hosting MEP and a member of the Special Cancer Committee, said:

“I want to thank I-Com for the study just published that highlights how prevention policies aimed at reducing risk factors have a lot of potential to help Europe beat cancer. The Special Cancer Committee and the European Parliament welcome the study findings aimed to contribute to the future actions orientation of the Beating Cancer Plan. Our wish is for the Parliament to play a key role in developing the Plan in effective and fruitful coordination with the European Commission.”

Commenting on the roundtable, Stefano da Empoli, President of I-Com, said:

“We were delighted to present our recommendations on how harm reduction can support the prevention of cancer. It is now clear that public health experts, policymakers and academics all support the inclusion of harm reduction policies to help prevent cancer and mitigate the harm caused by tobacco, alcohol and unhealthy diets. Legislators must, at all times, keep patients at the forefront of their minds. Now is the time to embrace harm reduction.”

Margratis Schinas, European Commissioner for Promoting the European Way of Life, said:

“Our aim for the Plan is that cancer should no longer mean chances
fading away, dropping out from projects, or stigmatisation.
Instead, one day, cancer shall mean accessible treatment, recovery
and, therefore, life opportunities for all affected people.
And this is possible. Up to 40% of cancers can be prevented.”

I-Com’s recommended best practices in minimising the harms caused by alcohol, tobacco and nutrition, include reducing the availability of alcohol, increasing the availability of smokeless tobacco products and building infrastructure promoting physical activity.

ABOUT I-COM

The Institute for Competitiveness (I-Com) is an Italian independent think tank based in Rome and Brussels, founded in 2005 by a group of scholars, professionals and managers. I-Com aims at influencing the public debate at the national, European and international level, analysing the most important drivers for competitiveness and growth.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release

EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia

Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release

Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release

FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release

In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye